Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference


TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) —

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that

Dr. Klaus Paulini, Chief Executive Officer

of Aeterna Zentaris, will present at the

H.C. Wainwright Global Investment Conference

being held May 23-26, 2022 in Miami, FL and virtually.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the

conference website

.

A

video webcast

of the presentation will be accessible for viewing on-demand beginning on Tuesday, May 24, 2022, at 7:00 AM ET for those registered for the event and will be available on the

Events

page in the

Investors

section of the Company’s website (

zentaris.com

). The webcast replay will be archived for 90 days following the event.


About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company’s lead product, macimorelin (Macrilen



; Ghryvelin

®

), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pre-clinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson’s disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig’s disease). Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and

Chlamydia


trachomatis

.

For more information, please visit

www.zentaris.com

and connect with the Company on

Twitter

,

LinkedIn

and

Facebook

.


Investor Contact:

Jenene Thomas

JTC Team

T (US): +1 (833) 475-8247

E:

[email protected]


Primary Logo